Merck pays J&J $500mn in drug row settlement

April 15, 2011

Merck said Friday it has agreed to pay fellow US pharmaceutical giant Johnson & Johnson $500 million to end a two-year tussle over profit-sharing deals for two anti-inflammatory drugs.

The resolution ends a dispute over the Remicade and Simponi drugs, which treat chronic inflammatory diseases such as rheumatoid arthritis, which began in May 2009 when J&J launched an arbitration process.

Johnson & Johnson "will... receive a one-time payment of $500 million (346 million euros) in April 2011," the companies said in a statement.

Friday's deal also amends the marketing rights for the two drugs between the two companies.

Under the new terms, Merck keeps its right to market the drugs in Europe, Russia and Turkey while Johnson & Johnson retains the marketing rights in the United States.

In addition, however, Johnson & Johnson will get the marketing rights in Africa, Asia, Canada, Central and South America and the Middle East, along with the one-off payment.

Furthermore, Johnson & Johnson will get half of the profits earned on the two drugs in Merck's territories.

Previously the two companies shared the global rights, with Merck receiving 58 percent of sales income and the other 42 percent going to Johnson subsidiary Centocor Ortho Biotech Inc.

In the joint statement issued by Merck, both company CEOs said they were "pleased to have reached" the agreement.

"These important medicines provide very meaningful benefit to the patients who depend upon them, and our first priority will be to ensure the continued availability... to healthcare providers and patients around the world," said Johnson & Johnson chief executive officer Bill Weldon, Chairman and Chief Executive Officer,

"We are working closely with to make certain this is a seamless transition in the relinquished territories," he added.

Explore further: Summer time and the living is breezy

Related Stories

Summer time and the living is breezy

June 6, 2006

The U.S. hurricane season is under way and for many people in areas hit hard by 2005's hurricanes, it's going to be an uneasy summer.

New HIV drugs on the way

March 1, 2007

U.S. researchers say promising new medicines are headed to the market that can help overcome increasing resistance to some HIV therapies.

Johnson & Johnson plans to buy Dutch vaccine group

September 17, 2010

US cosmetics and pharmaceutical giant Johnson & Johnson said on Friday it intended to acquire a Dutch vaccine maker Crucell which is active in developing countries for about 1.75 billion euros.

Johnson & Johnson, Crucell biotech announce takeover

October 6, 2010

Pharmaceutical and health care giant Johnson & Johnson has reached a deal with Dutch biotechnology vaccine group Crucell to buy 82.5 percent of Crucell for about 1.75 billion euros, the two firms said on Wednesday.

Johnson & Johnson complete friendly takeover of Crucell

February 22, 2011

Pharmaceutical and health care giant Johnson & Johnson announced Tuesday the successful completion of a friendly takeover of Dutch vaccine maker Crucell, for about 1.75 billion euros ($2.37 billion).

Recommended for you

Cow embryos reveal new type of chromosome chimera

May 27, 2016

I've often wondered what happens between the time an egg is fertilized and the time the ball of cells that it becomes nestles into the uterine lining. It's a period that we know very little about, a black box of developmental ...

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Shaving time to test antidotes for nerve agents

February 29, 2016

Imagine you wanted to know how much energy it took to bike up a mountain, but couldn't finish the ride to the peak yourself. So, to get the total energy required, you and a team of friends strap energy meters to your bikes ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Apr 15, 2011

It causes me great concern that there is such a tremendous amount of money attached to the health industry. The fact that there of billions of dollars at stake in the production and sale of pharmaceuticals would lead me to believe that manufacturers may have interests other than their consumers well being. The sheer volume of drug recalls that place each year is an indication, at least to me, that the pharmaceutical companies adhere to sell-now-ask-questions-later ethos. I recently stumbled upon a site that has compiled all drug recalls for the last several years (, I was shocked by the sheer volume as well as the ubiquitous nature of the drugs that were recalled.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.